|

bi-4SCAR CD19/22 T cells Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Shenzhen Geno-Immune Medical Institute1

Indications

  • B-cell Malignancies1
  • Cancer1

Other1 trial

CD19/22 Bi-specific CAR-T Cell Therapy
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.